{"id":"dasabuvir-mini-tablet","safety":{"commonSideEffects":[{"rate":"10%","effect":"Fatigue"},{"rate":"8%","effect":"Nausea"},{"rate":"6%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Dasabuvir is a non-nucleoside inhibitor of the NS5A protein of the hepatitis C virus, which is essential for viral replication.","oneSentence":"NS5A replication complex inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:23.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"}]},"trialDetails":[{"nctId":"NCT02486406","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-28","conditions":"Chronic Hepatitis C Infection","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Exviera","ABT-333"],"phase":"phase_2","status":"active","brandName":"Dasabuvir mini tablet","genericName":"Dasabuvir mini tablet","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NS5A replication complex inhibitor Used for Chronic hepatitis C.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}